Clinical Trials · NCT05478252
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 388
- Start date
- Aug 2022
- Locations
- 104 sites, 5 countries
- Primary endpoint
- Change in Glycosylated Haemoglobin (HbA1c)